Stock Information Data is 15 minutes delayed
ContraFect Corporation — Common Stock
Nasdaq: CFRX
Price
Change
Market Cap
Volume
Company Overview
ContraFect is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of direct lytic agents (DLAs), which include lysins and amurin peptides. We believe DLAs provide the opportunity to make meaningful improvements to clinical outcomes and to change the treatment paradigm for patients infected with antibiotic-resistant bacteria. Our initial product candidates are new agents to treat lethal, resistant infections such as methicillin-resistant Staph aureus (MRSA) and Gram-negative pathogens like multi-drug resistant (MDR) Pseudomonas aeruginosa.
Officers & Directors
Jane E. Ambler, Ph.D.
Vice President of Clinical Microbiology
Dr. Ambler has served as our Vice President of Clinical Microbiology since February 2020. Dr. Ambler has over 25 years of experience working in antibacterial drug development in the pharmaceutical industry and a hospital antibi...
View Full Profile »
Natalie Bogdanos J.D.
General Counsel, Corporate Secretary & Data Protection Officer
Ms. Bogdanos has served as our General Counsel and Corporate Secretary since August 2014, and served as our Data Protection Officer since July 2018. She has over 20 years of experience in the legal field, at least 15 of which w...
View Full Profile »
Nancy Capra
Vice President of Program Management and Development Operations
Ms. Capra has served as our Vice President of Program Management and Development Operations since February 2021. Prior to that, she had served as Executive Director of Program Management since November 2015. Ms. Capra is a Cert...
View Full Profile »
Michael Messinger, CPA
Chief Financial Officer
Mr. Messinger has served as our Chief Financial Officer since November 2018. Prior to that, he had served as Vice President of Finance since November 2012. Mr. Messinger has more than 20 years of experience in finance and accou...
View Full Profile »
W. Garrett Nichols, M.D., M.S.
Interim Chief Medical Officer
Dr. Nichols joined ContraFect as our Interim Medical Officer in August 2022. With more than 20 years in the life sciences industry, Dr. Nichols brings vast experience managing the global development efforts of multiple ca...
View Full Profile »
Roger J. Pomerantz, M.D., F.A.C.P.
President, Chief Executive Officer and Chairman of the Board
Dr. Pomerantz has served as Chairman of our board of directors and our Chief Executive Officer since April 2019. Prior to that, he had served as Vice Chairman of our board of directors since May 2014. From November 2013 to Dece...
View Full Profile »
Matthew Salamone, SPHR, PHR
Vice President of Human Resources
Mr. Salamone joined ContraFect in October 2020 and currently serves as our Vice President of Human Resources. He brings over 15 years of experience being a strategic partner within management and executive teams, assistin...
View Full Profile »
Raymond Schuch, Ph.D.
Vice President of Research
Dr. Schuch joined ContraFect in 2011 as the VP of Research where his work has supported the continued development of exebacase from IND candidacy through to our ongoing Phase 3 clinical trial. Prior to ContraFect, Dr. Schuch he...
View Full Profile »
Gary Woodnutt, Ph.D.
Senior Vice President of Translational Sciences and Preclinical Development
Dr. Woodnutt joined ContraFect in June 2021 as the Senior Vice President of Translational Sciences and Preclinical Development. He brings over 30 years of experience leading the discovery and development of innovative therapies...
View Full Profile »
Roger J. Pomerantz, M.D., F.A.C.P.
President, Chief Executive Officer and Chairman of the Board
Dr. Pomerantz has served as Chairman of our board of directors and our Chief Executive Officer since April 2019. Prior to that, he had served as Vice Chairman of our board of directors since May 2014. From November 2013 to Dece...
View Full Profile »
Sol J. Barer, Ph.D.
Lead Independent Director
Dr. Barer joined Celanese Research Company in 1974 and formed the Biotechnology Group that was spun out to form Celgene. Dr. Barer was Chairman and Chief Executive Officer from May 1, 2006 until June 16, 2010 and served as Exec...
View Full Profile »
Steven C. Gilman, Ph.D.
Vice Chairman of the Board
Dr. Gilman has served on the board of directors since May 2015. He was Chief Executive Officer and Chairman of the board of directors from May 2015 until April 2019. Prior to ContraFect, he served as the Executive Vice Presiden...
View Full Profile »
Cary W. Sucoff, J.D.
Director
Mr. Sucoff has served as a member of our board of directors since May 2010. Mr. Sucoff has more than 30 years of securities industry experience encompassing supervisory, banking and sales responsibilities. He has participated i...
View Full Profile »
David N. Low, Jr.
Director
Mr. Low has served as a member of our board of directors since April 2014. Mr. Low has worked as an investment banker since 1987, with broad investment and advisory experience in the life sciences, biotechnology and medical tec...
View Full Profile »
Michael J. Otto, Ph.D.
Director
Dr. Otto has served as a member of our board of directors since April 2014. Most recently, he was Chief Scientific Officer of Pharmasset from October 1999 until February 2012, when the company was acquired by Gilead Sciences. H...
View Full Profile »
Lishan Aklog, M.D.
Director
Dr. Aklog is Co-Founder, Chairman and Chief Executive Officer of PAVmed Inc. (Nasdaq: PAVM). Dr. Aklog has served as Executive Chairman of Lucid Diagnostics Inc. since its inception in 2018, as a co-founding Partner of both Pav...
View Full Profile »
Jane F. Barlow, MD, MPH, MBA
Director
Dr. Barlow is currently the Chief Executive Officer of Jane Barlow & Associates, LLC, Executive Vice President and Chief Clinical Officer at Real Endpoints. She is a senior advisory to MIT’s Center for Biomedical Innovati...
View Full Profile »Annaliesa Anderson, PhD, FAAM
Science & Technology Committee Observer
Dr. Anderson is an Observer on our Science & Technology Committee. She has over 20 years of pharmaceutical research and development experience and is currently the Vice President and Chief Scientific Officer for Bacte...
View Full Profile »